Diagnosis | Timing of presentation | Modified WHO class | NYHA class | Age (years) | EF (%) | When | Reason | Fetal outcome |
---|---|---|---|---|---|---|---|---|
PPCM with subsequent pregnancy | Prepartum | IV | II | 24 | 45 | 61 days postpartum | Sudden death | Fetal survival |
PPCM | Postpartum | IV | II | 32 | 32 | 130 days postpartum | CCF | Fetal survival |
Rheumatic HD with DVR | Prepartum | IV | I | 19 | 30 | 50 days postpartum | Valve thrombosis | Fetal survival |
PPCM | Postpartum | IV | III | 24 | 24 | 122 days postpartum | CCF | Fetal survival |
Familial CMO | Prepartum | IV | II | 43 | 30 | 44 day spostpartum | CCF | Fetal survival |
PPCM | Prepartum | IV | II | 32 | 25 | 95 days postpartum | Sudden death | Fetal survival |
Familial CMO | Prepartum | IV | III | 25 | 26 | 92 days postpartum | CCF | Fetal survival |
PPCM post miscarriage | Postpartum | IV | IV | 24 | 31 | 150 postpartum | CCF | Miscarriage 20 weeks |
Rheumatic HD with MVR | Prepartum | IV | I | 25 | 60 | 16 weeks prepartum | SBE | Fetal death |
CCF, congestive cardiac failure; CMO, cardiomyopathy; DVR, double valve replacement; HD, heart disease; MVR, mitral valve replacement; NYHA, New York Heart Association; PPCM, peripartum cardiomyopathy; SBE, subacute bacterial endocardititis.